Recently, we demonstrated that binding of GnRH-I (a classical form of GnRH) and GnRH-II (a second form of GnRH) to the GnRH-I receptor activates ERK1/2 through a PKC-dependent pathway and is essential for GnRH-induced anti-proliferation of ovarian cancer cells [20]. The gene discussed is PRRT2; the disease is ovarian carcinoma.